← all works
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- The Lancet
- Topic
- Diabetes Treatment and Management
- Field
- Medicine
- Canadian institutions
- St. Michael's HospitalInstitut universitaire de cardiologie et de pneumologie de QuébecPopulation Health Research InstituteUniversité LavalUniversity of TorontoHamilton Health SciencesMcMaster University
- Funders
- Eli Lilly and Company
- Keywords
- DulaglutideMedicineType 2 diabetesInternal medicineClinical endpointPlaceboPopulationMyocardial infarctionDiabetes mellitusStroke (engine)Adverse effectSemaglutideRandomized controlled trialPhysical therapyExenatideLiraglutideEndocrinology
- Has abstract in OpenAlex
- no